Article
End-of-life targeted degradation of DAF-2 insulin/IGF-1 receptor promotes longevity free from growth-related pathologies.
eLife - 10 Sept 2021
Venz Richard, Pekec Tina, Katic Iskra, Ciosk Rafal, Ewald Collin Yvès
Abstract excerpt
Preferably, lifespan-extending therapies should work when applied late in life without causing undesired pathologies. Reducing insulin/insulin-like growth factor (IGF)-1 signaling (IIS) increases lifespan across species, but the effects of reduced IIS interventions in extreme geriatric ages remains unknown. Using the nematode Caenorhabditis elegans, we engineered the conditional depletion of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
